HEADER HYDROLASE 29-NOV-04 1WU1 TITLE FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5-CHLOROINDOL-2-YL) TITLE 2 SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL) PYRIMIDIN-2- TITLE 3 YL]CARBONYL]PIPERAZINE COMPND MOL_ID: 1; COMPND 2 MOLECULE: COAGULATION FACTOR X, HEAVY CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 16-243; COMPND 5 SYNONYM: STUART FACTOR, STUART-PROWER FACTOR; COMPND 6 EC: 3.4.21.6; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: COAGULATION FACTOR X, LIGHT CHAIN; COMPND 9 CHAIN: B; COMPND 10 FRAGMENT: RESIDUES 85-138; COMPND 11 SYNONYM: STUART FACTOR, STUART-PROWER FACTOR; COMPND 12 EC: 3.4.21.6 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 MOL_ID: 2; SOURCE 6 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 7 ORGANISM_COMMON: HUMAN; SOURCE 8 ORGANISM_TAXID: 9606; SOURCE 9 OTHER_DETAILS: PROTEOLYTIC CLEAVAGE PRODUCT KEYWDS GLYCOPROTEIN, HYDROLASE, SERINE PROTEASE, PLASMA, BLOOD COAGULATION KEYWDS 2 FACTOR, PROTEIN INHIBITOR COMPLEX, CALCIUM-BINDING EXPDTA X-RAY DIFFRACTION AUTHOR M.SUZUKI REVDAT 4 25-OCT-23 1WU1 1 REMARK LINK REVDAT 3 20-JUN-12 1WU1 1 HETNAM VERSN REVDAT 2 24-FEB-09 1WU1 1 VERSN REVDAT 1 29-NOV-05 1WU1 0 JRNL AUTH S.KOMORIYA,N.HAGINOYA,S.KOBAYASHI,T.NAGATA,A.MOCHIZUKI, JRNL AUTH 2 M.SUZUKI,T.YOSHINO,H.HORINO,T.NAGAHARA,M.SUZUKI,Y.ISOBE, JRNL AUTH 3 T.FURUGOORI JRNL TITL DESIGN, SYNTHESIS, AND BIOLOGICAL ACTIVITY OF NON-BASIC JRNL TITL 2 COMPOUNDS AS FACTOR XA INHIBITORS: SAR STUDY OF S1 AND ARYL JRNL TITL 3 BINDING SITES JRNL REF BIOORG.MED.CHEM. V. 13 3927 2005 JRNL REFN ISSN 0968-0896 JRNL PMID 15911309 JRNL DOI 10.1016/J.BMC.2005.04.006 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH K.KAMATA,H.KAWAMOTO,T.HONMA,T.IWAMA,S.H.KIM REMARK 1 TITL STRUCTURAL BASIS FOR CHEMICAL INHIBITION OF HUMAN BLOOD REMARK 1 TITL 2 COAGULATION FACTOR XA REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 95 6630 1998 REMARK 1 REFN ISSN 0027-8424 REMARK 1 PMID 9618463 REMARK 1 DOI 10.1073/PNAS.95.12.6630 REMARK 1 REFERENCE 2 REMARK 1 AUTH H.BRANDSTETTER,A.KUHNE,W.BODE,R.HUBER,W.VON DER SAAL, REMARK 1 AUTH 2 K.WIRTHENSOHN,R.A.ENGH REMARK 1 TITL X-RAY STRUCTURE OF ACTIVE SITE-INHIBITED CLOTTING FACTOR XA. REMARK 1 TITL 2 IMPLICATIONS FOR DRUG DESIGN AND SUBSTRATE RECOGNITION REMARK 1 REF J.BIOL.CHEM. V. 271 29988 1996 REMARK 1 REFN ISSN 0021-9258 REMARK 1 PMID 8939944 REMARK 1 DOI 10.1074/JBC.271.47.29988 REMARK 1 REFERENCE 3 REMARK 1 AUTH K.PADMANABHAN,K.P.PADMANABHAN,A.TULINSKY,C.H.PARK,W.BODE, REMARK 1 AUTH 2 R.HUBER,D.T.BLANKENSHIP,A.D.CARDIN,W.KISIEL REMARK 1 TITL STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 A RESOLUTION REMARK 1 REF J.MOL.BIOL. V. 232 947 1993 REMARK 1 REFN ISSN 0022-2836 REMARK 1 PMID 8355279 REMARK 1 DOI 10.1006/JMBI.1993.1441 REMARK 1 REFERENCE 4 REMARK 1 AUTH N.HAGINOYA,S.KOBAYASHI,S.KOMORIYA,T.YOSHINO,M.SUZUKI, REMARK 1 AUTH 2 T.SHIMADA,K.WATANABE,Y.HIROKAWA,T.FURUGORI,T.NAGAHARA REMARK 1 TITL SYNTHESIS AND CONFORMATIONAL ANALYSIS OF A NON-AMIDINE REMARK 1 TITL 2 FACTOR XA INHIBITOR THAT INCORPORATES REMARK 1 TITL 3 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE AS S4 REMARK 1 TITL 4 BINDING ELEMENT REMARK 1 REF J.MED.CHEM. V. 47 5167 2004 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM049884D REMARK 2 REMARK 2 RESOLUTION. 2.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0005 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 25.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 12933 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.191 REMARK 3 R VALUE (WORKING SET) : 0.189 REMARK 3 FREE R VALUE : 0.235 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 697 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 15 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.30 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.38 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1203 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 100.0 REMARK 3 BIN R VALUE (WORKING SET) : 0.2080 REMARK 3 BIN FREE R VALUE SET COUNT : 65 REMARK 3 BIN FREE R VALUE : 0.3070 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2155 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 76 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 45.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.31000 REMARK 3 B22 (A**2) : -1.70000 REMARK 3 B33 (A**2) : 1.39000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.338 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.231 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.166 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 6.604 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.942 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.912 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2245 ; 0.022 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3050 ; 2.116 ; 1.962 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 285 ; 7.279 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 90 ;36.164 ;24.111 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 351 ;18.214 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 10 ;30.158 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 333 ; 0.130 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 1702 ; 0.008 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 1019 ; 0.250 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1573 ; 0.328 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 156 ; 0.183 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): 6 ; 0.215 ; 0.200 REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 21 ; 0.211 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 12 ; 0.149 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1439 ; 1.930 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2264 ; 3.175 ; 2.500 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 918 ; 2.648 ; 2.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 786 ; 3.961 ; 3.000 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL PARAMETERS FOR MASK CACLULATION REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : NULL REMARK 3 ION PROBE RADIUS : NULL REMARK 3 SHRINKAGE RADIUS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1WU1 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 02-DEC-04. REMARK 100 THE DEPOSITION ID IS D_1000023997. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 13-APR-99 REMARK 200 TEMPERATURE (KELVIN) : 293.0 REMARK 200 PH : 5.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU200 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.542 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IIC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : D*TREK REMARK 200 DATA SCALING SOFTWARE : D*TREK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 13656 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.300 REMARK 200 RESOLUTION RANGE LOW (A) : 39.510 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 90.6 REMARK 200 DATA REDUNDANCY : 2.900 REMARK 200 R MERGE (I) : 0.06400 REMARK 200 R SYM (I) : 0.33800 REMARK 200 FOR THE DATA SET : 11.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.30 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.38 REMARK 200 COMPLETENESS FOR SHELL (%) : 84.3 REMARK 200 DATA REDUNDANCY IN SHELL : 2.89 REMARK 200 R MERGE FOR SHELL (I) : 0.33800 REMARK 200 R SYM FOR SHELL (I) : 0.33800 REMARK 200 FOR SHELL : 2.890 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: RIGID BODY REFINEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: 1FAX REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 44.21 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.20 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG6000, NAACETATE, PH 5.00, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.28450 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.51000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.24350 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.51000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.28450 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.24350 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 LYS B 45 REMARK 465 ASP B 46 REMARK 465 GLY B 47 REMARK 465 ASP B 48 REMARK 465 GLN B 49 REMARK 465 CYS B 50 REMARK 465 GLU B 51 REMARK 465 THR B 52 REMARK 465 SER B 53 REMARK 465 PRO B 54 REMARK 465 CYS B 55 REMARK 465 GLN B 56 REMARK 465 ASN B 57 REMARK 465 GLN B 58 REMARK 465 GLY B 59 REMARK 465 LYS B 60 REMARK 465 CYS B 61 REMARK 465 LYS B 62 REMARK 465 BHD B 63 REMARK 465 GLY B 64 REMARK 465 LEU B 65 REMARK 465 GLY B 66 REMARK 465 GLU B 67 REMARK 465 TYR B 68 REMARK 465 THR B 69 REMARK 465 CYS B 70 REMARK 465 THR B 71 REMARK 465 CYS B 72 REMARK 465 LEU B 73 REMARK 465 GLU B 74 REMARK 465 GLY B 75 REMARK 465 PHE B 76 REMARK 465 GLU B 77 REMARK 465 GLY B 78 REMARK 465 LYS B 79 REMARK 465 ASN B 80 REMARK 465 CYS B 81 REMARK 465 GLU B 82 REMARK 465 LEU B 83 REMARK 465 PHE B 84 REMARK 465 ARG B 139 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 20 OE1 NE2 REMARK 470 GLU A 36 OE1 OE2 REMARK 470 GLU A 37 CG CD OE1 OE2 REMARK 470 ASN A 38 OD1 ND2 REMARK 470 GLU A 39 CG CD OE1 OE2 REMARK 470 LYS A 62 CG CD CE NZ REMARK 470 ARG A 63 CG CD NE CZ NH1 NH2 REMARK 470 GLN A 75 OE1 NE2 REMARK 470 GLU A 76 CD OE1 OE2 REMARK 470 ASN A 92 OD1 ND2 REMARK 470 ARG A 93 NE CZ NH1 NH2 REMARK 470 LYS A 96 CG CD CE NZ REMARK 470 GLU A 97 CG CD OE1 OE2 REMARK 470 SER A 130 OG REMARK 470 LYS A 134 CD CE NZ REMARK 470 LYS A 148 CD CE NZ REMARK 470 ARG A 150 CG CD NE CZ NH1 NH2 REMARK 470 GLN A 187 OE1 NE2 REMARK 470 ARG A 202 CZ NH1 NH2 REMARK 470 LYS A 223 CG CD CE NZ REMARK 470 LYS A 236 CG CD CE NZ REMARK 470 ARG B 86 CG CD NE CZ NH1 NH2 REMARK 470 LYS B 87 CG CD CE NZ REMARK 470 GLN B 104 CG CD OE1 NE2 REMARK 470 ARG B 113 CG CD NE CZ NH1 NH2 REMARK 470 GLU B 138 CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 CYS B 109 CB CYS B 109 SG -0.129 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 154 NE - CZ - NH2 ANGL. DEV. = 3.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 24 117.63 -39.09 REMARK 500 GLU A 37 9.85 -69.67 REMARK 500 ARG A 115 -177.57 179.75 REMARK 500 LYS A 204 -118.25 51.56 REMARK 500 SER A 214 -70.68 -110.60 REMARK 500 LEU B 88 -124.09 36.82 REMARK 500 ASN B 93 16.38 56.35 REMARK 500 GLN B 98 -110.97 -138.41 REMARK 500 GLN B 104 -131.29 64.80 REMARK 500 LEU B 137 -35.06 -170.49 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 D91 A 700 REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 CA A 261 CA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 70 OD1 REMARK 620 2 ASN A 72 O 85.4 REMARK 620 3 GLN A 75 O 141.2 76.1 REMARK 620 4 GLU A 77 OE2 98.1 79.1 111.1 REMARK 620 5 GLU A 80 OE2 78.1 157.6 107.9 117.9 REMARK 620 6 HOH A 355 O 79.6 89.2 66.6 168.2 73.1 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 CA A 262 CA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 TYR A 185 O REMARK 620 2 ASP A 185A O 77.7 REMARK 620 3 ARG A 222 O 154.0 78.6 REMARK 620 4 LYS A 224 O 88.7 109.5 89.4 REMARK 620 5 HOH A 337 O 94.4 171.5 108.5 66.6 REMARK 620 6 HOH A 367 O 111.5 86.4 77.2 157.0 99.7 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA A 261 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA A 262 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE D91 A 700 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1V3X RELATED DB: PDB REMARK 900 THE SAME PROTEIN COMPLEXED WITH STRUCTURALLY RELATED INHIBITOR DBREF 1WU1 A 16 243 UNP P00742 FA10_HUMAN 235 467 DBREF 1WU1 B 45 139 UNP P00742 FA10_HUMAN 85 179 SEQRES 1 A 233 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 A 233 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 A 233 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 A 233 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 A 233 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 A 233 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 A 233 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 A 233 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 A 233 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 A 233 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 A 233 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 A 233 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 A 233 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 A 233 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 A 233 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 A 233 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 A 233 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 A 233 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS SEQRES 1 B 95 LYS ASP GLY ASP GLN CYS GLU THR SER PRO CYS GLN ASN SEQRES 2 B 95 GLN GLY LYS CYS LYS BHD GLY LEU GLY GLU TYR THR CYS SEQRES 3 B 95 THR CYS LEU GLU GLY PHE GLU GLY LYS ASN CYS GLU LEU SEQRES 4 B 95 PHE THR ARG LYS LEU CYS SER LEU ASP ASN GLY ASP CYS SEQRES 5 B 95 ASP GLN PHE CYS HIS GLU GLU GLN ASN SER VAL VAL CYS SEQRES 6 B 95 SER CYS ALA ARG GLY TYR THR LEU ALA ASP ASN GLY LYS SEQRES 7 B 95 ALA CYS ILE PRO THR GLY PRO TYR PRO CYS GLY LYS GLN SEQRES 8 B 95 THR LEU GLU ARG HET CA A 261 1 HET CA A 262 1 HET D91 A 700 33 HETNAM CA CALCIUM ION HETNAM D91 5-CHLORO-2-({3-ISOBUTYL-4-[(5-PYRIDIN-4-YLPYRIMIDIN-2- HETNAM 2 D91 YL)CARBONYL]PIPERAZIN-1-YL}SULFONYL)-1H-INDOLE HETSYN D91 4-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1- HETSYN 2 D91 [[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE FORMUL 3 CA 2(CA 2+) FORMUL 5 D91 C26 H27 CL N6 O3 S FORMUL 6 HOH *76(H2 O) HELIX 1 1 ALA A 55 GLN A 61 5 7 HELIX 2 2 GLU A 124A LEU A 131A 1 9 HELIX 3 3 ASP A 164 SER A 172 1 9 HELIX 4 4 PHE A 234 MET A 242 1 9 HELIX 5 5 LYS B 87 CYS B 96 5 10 SHEET 1 A 7 GLN A 20 GLU A 21 0 SHEET 2 A 7 LYS A 156 PRO A 161 -1 O MET A 157 N GLN A 20 SHEET 3 A 7 THR A 135 GLY A 140 -1 N GLY A 140 O LYS A 156 SHEET 4 A 7 PRO A 198 PHE A 203 -1 O VAL A 200 N ILE A 137 SHEET 5 A 7 THR A 206 GLY A 216 -1 O THR A 206 N PHE A 203 SHEET 6 A 7 GLY A 226 LYS A 230 -1 O ILE A 227 N TRP A 215 SHEET 7 A 7 MET A 180 ALA A 183 -1 N ALA A 183 O GLY A 226 SHEET 1 B 7 GLN A 30 ILE A 34 0 SHEET 2 B 7 GLY A 40 ILE A 46 -1 O GLY A 44 N ALA A 31 SHEET 3 B 7 TYR A 51 THR A 54 -1 O LEU A 53 N THR A 45 SHEET 4 B 7 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 5 B 7 ALA A 81 LYS A 90 -1 N GLU A 86 O ARG A 107 SHEET 6 B 7 LYS A 65 VAL A 68 -1 N VAL A 66 O HIS A 83 SHEET 7 B 7 GLN A 30 ILE A 34 -1 N LEU A 32 O ARG A 67 SHEET 1 C 2 PHE B 99 GLU B 103 0 SHEET 2 C 2 SER B 106 SER B 110 -1 O VAL B 108 N HIS B 101 SHEET 1 D 2 TYR B 115 LEU B 117 0 SHEET 2 D 2 CYS B 124 PRO B 126 -1 O ILE B 125 N THR B 116 SSBOND 1 CYS A 22 CYS A 27 1555 1555 1.99 SSBOND 2 CYS A 42 CYS A 58 1555 1555 2.02 SSBOND 3 CYS A 122 CYS B 132 1555 1555 1.98 SSBOND 4 CYS A 168 CYS A 182 1555 1555 1.98 SSBOND 5 CYS A 191 CYS A 220 1555 1555 2.01 SSBOND 6 CYS B 89 CYS B 100 1555 1555 2.03 SSBOND 7 CYS B 96 CYS B 109 1555 1555 1.97 SSBOND 8 CYS B 111 CYS B 124 1555 1555 2.00 LINK OD1 ASP A 70 CA CA A 261 1555 1555 2.23 LINK O ASN A 72 CA CA A 261 1555 1555 2.53 LINK O GLN A 75 CA CA A 261 1555 1555 2.57 LINK OE2 GLU A 77 CA CA A 261 1555 1555 2.05 LINK OE2 GLU A 80 CA CA A 261 1555 1555 2.31 LINK O TYR A 185 CA CA A 262 1555 1555 2.18 LINK O ASP A 185A CA CA A 262 1555 1555 3.01 LINK O ARG A 222 CA CA A 262 1555 1555 2.47 LINK O LYS A 224 CA CA A 262 1555 1555 2.28 LINK CA CA A 261 O HOH A 355 1555 1555 2.30 LINK CA CA A 262 O HOH A 337 1555 1555 2.88 LINK CA CA A 262 O HOH A 367 1555 1555 2.45 SITE 1 AC1 7 ASP A 70 ASN A 72 GLN A 75 GLU A 76 SITE 2 AC1 7 GLU A 77 GLU A 80 HOH A 355 SITE 1 AC2 6 TYR A 185 ASP A 185A ARG A 222 LYS A 224 SITE 2 AC2 6 HOH A 337 HOH A 367 SITE 1 AC3 16 GLU A 97 THR A 98 TYR A 99 PHE A 174 SITE 2 AC3 16 ASP A 189 ALA A 190 GLN A 192 VAL A 213 SITE 3 AC3 16 TRP A 215 GLY A 216 GLU A 217 GLY A 218 SITE 4 AC3 16 CYS A 220 GLY A 226 ILE A 227 TYR A 228 CRYST1 56.569 72.487 79.020 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017678 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013796 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012655 0.00000